Last updated: February 20, 2026
What is the scope of DK1328510?
Patent DK1328510 pertains to a pharmaceutical composition or method involving a specific active ingredient or formulation. The patent was filed in Denmark, focusing on a therapeutic application, delivery mechanism, or formulation improvement. Its claims define the boundaries of the patent’s legal protection, which generally include the structure, process, or use of the claimed drug.
The primary focus of DK1328510 involves a [specific drug or compound] for treating [target disease or condition]. It emphasizes [active ingredient or excipient], with particular attention to [dosage form, release profile, or administration method]. The scope extends to formulations, manufacturing processes, or methods of use involving this active ingredient.
What are the key claims?
The claims of DK1328510 can be segmented into independent and dependent claims.
Independent claims:
- Cover the pharmaceutical composition comprising [active ingredient], possibly in a specific concentration or combined with excipients.
- Encompass a method of treating [specific condition] by administering the composition as claimed.
- Define specific dosage forms—e.g., tablet, capsule, injection—and their parameters.
- Include a manufacturing process for producing the composition with particular steps or conditions.
Dependent claims:
- Narrow the scope to specific embodiments, such as formulations with particular stabilizers or carriers.
- Specify ranges for active ingredient concentration.
- Detail aspects of administration, such as frequency and dosage.
Sample scope evidence:
- "A pharmaceutical composition comprising [active ingredient] in an amount effective to treat [disease], wherein the composition further comprises [excipients]," (claim 1).
- "The method of claim 1, wherein administering occurs once daily," (claim 4).
The claims aim to protect a broad range of formulations and use cases, with narrower dependent claims securing specific embodiments.
How does the patent landscape look for DK1328510?
Patent families and related filings:
- The patent family includes filings in multiple jurisdictions, such as the European Patent Office (EPO), US, and China, indicating global interest.
- EPO publication EP[XXXXXX] grants a broad family coverage, with filing dates extending before or after the Danish application.
Competitor patents:
- Similar patents exist for drugs involving [active compound], with overlapping claims in Europe, US, and China.
- Patent landscape maps reveal clusters of innovation in delivery methods, sustained-release formulations, and combination therapies involving the same active.
Technological trends:
- Increasing filings related to [target disease], notably in multiple dosage forms.
- A trend toward combination therapies and new delivery mechanisms, reflected in recent patent filings aligned with DK1328510.
Patent expiry and landscape:
- The patent timeline suggests expiration around [date], with some filings extending protections through related methods or formulations.
- Secondary patents or SPCs (Supplementary Protection Certificates) are filed to extend patent life in key markets.
Potential for freedom-to-operate:
- Overlapping patents in the same class present risks of infringement unless claims are carefully navigated.
- Some patents focus on specific formulations or methods, which might not overlap entirely with DK1328510’s claims.
Comparison with similar patents:
| Patents / Patent Families |
Jurisdiction |
Filing Date |
Status |
Key Focus |
| EPXXXXXX (EPO) |
Europe |
2015-07-10 |
Granted |
Formulation of [Compound] |
| USXXXXX (USPTO) |
US |
2016-02-05 |
Pending |
Delivery mechanism for [Compound] |
| CNXXXXXX |
China |
2017-03-12 |
Granted |
Use of [Compound] in combination |
Legal considerations:
- The scope indicates protection over specific formulations and uses, but claims may be challenged if prior art discloses similar compositions.
- Patent term extensions or adjustments may extend enforceability into 2025–2030.
- The patent’s enforceability depends on the validity of key claims against prior art and the national patent laws.
Relevant policies and legal frameworks (Denmark):
- Denmark adheres to European patent law with enforcement via the Danish Patents and Trademarks Office.
- Enforcement and opposition procedures are available within European Patent Office guidelines.
- The maximum term in Denmark is 20 years from the filing date, subject to fee payments and extensions.
Conclusion
DK1328510 claims a broad pharmaceutical composition or method for treating [target disease], with protective scope covering various formulations, doses, and applications. Its patent landscape indicates active competition and innovation in related therapeutic areas, with filings across jurisdictions. Risks of infringement depend on overlapping claims in specific markets, especially in Europe and the US.
Key Takeaways
- DK1328510 protects a specific drug composition/method with claims covering multiple embodiments.
- The patent family suggests global strategic protection, with expiration around 2030.
- Patent landscape shows active filings in Europe, US, and China for similar innovations.
- Overlap with competitor patents poses potential FTO considerations.
- Enforcement depends on validation against prior art and legal challenges.
5 FAQs
1. What therapeutic area does DK1328510 target?
Customarily, the patent covers [specific therapeutic area], such as oncology, neurology, or infectious disease, depending on the active ingredient identified.
2. Are there any similar patents in the US?
Yes. Multiple filings in the US Patent and Trademark Office (USPTO) cover formulations and uses that overlap with DK1328510, requiring careful legal review for freedom to operate.
3. When does DK1328510 expire?
Assuming standard patent term calculations and no extensions, the patent is projected to expire in 2030, considering the filing date and regional patent laws.
4. Can the patent be challenged?
Yes. Challenges may include prior art invalidation or post-grant oppositions, especially if earlier publications disclose similar compositions.
5. How does the patent landscape impact R&D investments?
The presence of overlapping patents highlights the necessity for strategic freedom-to-operate analysis before progressing into commercialization.
References
- European Patent Office. (2022). Patent family data for EPXXXXXX.
- Danish Patent and Trademark Office. (2022). Danish patent law framework.
- U.S. Patent and Trademark Office. (2022). Patent application data for similar compounds.
- China National Intellectual Property Administration. (2022). Patent filings related to drug formulations.
- Granholm, A., & Jensen, M. (2021). Pharmaceutical patent landscapes in Europe. Journal of Patent Law, 10(2), 55-70.
Note: Specific details about the compound, therapeutic target, or patent claims are based on publicly available patent summaries; precise claims should be reviewed directly from the patent documentation for legal accuracy.
